2018
DOI: 10.1002/jlb.3ma1017-423r
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of soluble epoxide hydrolase attenuates eosinophil recruitment and food allergen-induced gastrointestinal inflammation

Abstract: Prevalence of food allergies in the United States is on the rise. Eosinophils are recruited to the intestinal mucosa in substantial numbers in food allergen-driven gastrointestinal (GI) inflammation. Soluble epoxide hydrolase (sEH) is known to play a pro-inflammatory role during inflammation by metabolizing anti-inflammatory epoxyeicosatrienoic acids (EETs) to pro-inflammatory diols. We investigated the role of sEH in a murine model of food allergy and evaluated the potential therapeutic effect of a highly sel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
15
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
8
1

Relationship

4
5

Authors

Journals

citations
Cited by 14 publications
(16 citation statements)
references
References 79 publications
1
15
0
Order By: Relevance
“…VECTASTAIN Elite ABC kit containing biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA), and the Peroxidase AEC (3-amino-9-ethylcarbazole) substrate kit (Vector Laboratories) were used for detection of bound antibodies. Expression of sEH in lungs of OVA-challenged mice (Ge et al, 2016) was detected as described previously (Bastan et al, 2018). In all cases, stained slides were examined using a Nikon Microphot EPI-FL microscope and images were captured with an Olympus DP71 camera.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…VECTASTAIN Elite ABC kit containing biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA), and the Peroxidase AEC (3-amino-9-ethylcarbazole) substrate kit (Vector Laboratories) were used for detection of bound antibodies. Expression of sEH in lungs of OVA-challenged mice (Ge et al, 2016) was detected as described previously (Bastan et al, 2018). In all cases, stained slides were examined using a Nikon Microphot EPI-FL microscope and images were captured with an Olympus DP71 camera.…”
Section: Methodsmentioning
confidence: 99%
“…Additionally, studies have shown that inhibition of sEH with a selective inhibitor attenuates ovalbumin (OVA)-induced eosinophilia, reduces levels of Th2 cytokines and chemokines, and improves airway resistance and compliance in mice (Yang et al, 2015). Along these lines, our recent studies have shown that expression of sEH is induced by food allergens in the gastrointestinal (GI) tract and that inhibition of sEH attenuates allergen-induced eosinophilia, mast cell recruitment and mucus secretion in the jejunum (Bastan et al, 2018). As such, identification of inhibitors targeting the COX-2 and sEH enzymatic pathways in the context of allergic airway disease is likely to yield valuable information contributing to the development of novel strategies to manage this disease.…”
Section: Introductionmentioning
confidence: 99%
“…Importantly, the sEH eicosanoid pathway has been suggested to be involved in the progression of colorectal cancer, including obesity-associated cancer ( Zhang, Sanidad, & Zhang, 2019 ). Inflammatory mediators, including angiotensin, TNF-α and NF-κB can upregulate sEH expression in immune cells ( Bastan et al, 2018 ). sEH inhibitors (sEHI) downregulate NF-κB and other inflammatory markers leading to decreased pro-inflammatory cytokines and nitric oxide metabolites and upregulates lipoxins to generate resolution ( Schmelzer et al, 2005 ).…”
Section: Therapeutic Approachesmentioning
confidence: 99%
“…Recent studies have yielded a better understanding of the role of sEH in regulating the progression of several diseases in preclinical studies (Luria et al, 2011; Imig, 2012, 2015; Wang et al, 2013, 2018; Ren et al, 2018). The inhibition of sEH demonstrates a promising approach to treat various diseases, including hypertension (Imig et al, 2005; Anandan et al, 2011), inflammation (Davis et al, 2011; Bastan et al, 2018), diabetes (Lorthioir et al, 2012; Hu et al, 2017), neuropathic pain (Hammock et al, 2011; McReynolds et al, 2016; Wagner K. et al, 2017; Wagner K. M. et al, 2017), and central nervous system (CNS) disorders (Simpkins et al, 2009; Ren et al, 2016; Zarriello et al, 2018). Growing evidence suggests that EpFAs reduce endoplasmic reticulum stress as a common underlying mechanism for these therapeutic effects (Yu et al, 2015; Inceoglu et al, 2017).…”
Section: Introductionmentioning
confidence: 99%